Genetic association analysis of N-methyl-d-aspartate receptor subunit gene GRIN2B and clinical response to clozapine

Human Psychopharmacology

Volumn 31, Issue 2, 2016, Pages 121-134

  Taylor, Danielle L ^a,b   Tiwari, Arun K ^a   Lieberman, Jeffrey A ^c   Potkin, Steven G ^d   Meltzer, Herbert Y ^e   Knight, Jo ^a,b,f   Remington, Gary ^a,f   Müller, Daniel J ^a,b,f   Kennedy, James L ^a,b,f  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Columbia University and the New York State Psychiatric Institute ^*  (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

clozapine; glutamate; GRIN2B; pharmacogenetics; schizophrenia

Indexed keywords

CLOZAPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; NR2B NMDA RECEPTOR;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; DRUG EFFECT; DSM-III-R; DSM-IV; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; CAUCASIAN; DRUG RESISTANCE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION STUDY; GENETICS; PSYCHOLOGICAL RATING SCALE;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84960120162     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2519     Document Type: Article

References (148)

1. Abrams DJ, Rojas DC, Arciniegas DB,. 2008. Is schizoaffective disorder a distinct categorical diagnosis? A critical review of the literature. Neuropsychiatric Disease Treatment 4 (6): 1089-1109.
2. Alonso P, Gratacos M, Segalas C, et al., 2012. Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder. J Psychiatry Neurosci 37 (4): 273-281.
3. Altar CA, Wasley AM, Neale RF, Stone GA,. 1986. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: An autoradiographic analysis in rat brain. Brain Res Bull 16 (4): 517-525.
4. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (DSM-V), 4th edn. American Psychiatric Association: Washington D.C.
5. American Psychiatric Association. 1987. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), 3rd edn. American Psychiatric Association (revised): Washington D.C.
6. American Psychiatric Association. 2013. Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 5th edn. American Psychiatric Publishing: Arlington, VA.
7. Anson LC, Chen PE, Wyllie DJ, Colquhoun D, Schoepfer R,. 1998. Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDA receptors. J Neurosci 18 (2): 581-589.
8. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY,. 1997. Clozapine and haloperidol modulate N-methyl-d-aspartate- A nd non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. Jl Pharmacol Exp Ther 283 (1): 226-234.
9. Asztely F, Gustafsson B,. 1996. Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Mol Neurobiol 12 (1): 1-11.
10. Ayalew M, Le-Niculescu H, Levey DF, et al., 2012. Convergent functional genomics of schizophrenia: From comprehensive understanding to genetic risk prediction. Mol Psychiatry 17 (9): 887-905.
11. Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI,. 1995. Glutamate agonist activity: Implications for antipsychotic drug action and schizophrenia. Neuroreport 6 (18): 2500-2504.
12. Barrett J, Fry B, Maller J, Daly M,. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2): 263-265.
13. Bertilsson L, Carrillo JA, Dahl ML, et al., 1994. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38 (5): 471-473.
14. Black IB,. 1999. Trophic regulation of synaptic plasticity. J Neurobiol 41 (1): 108-118.
15. Bleehen T,. 1993. Clozapine: Literature Review. Sandoz Pharma: Basel, Switzerland.
16. Borgio JG, Bressan RA, Barbosa Neto JB, Daltio CS,. 2007. Refractory schizophrenia: A neglected clinical problem. Rev Bras Psiquiatr (Sao Paulo Brazil 1999) 29 (3): 292-293.
17. Brown AS, Begg MD, Gravenstein S, et al., 2004. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 61 (8): 774-780.
18. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH,. 2001. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry 58 (11): 1032-1037.
19. Cai J, Zhang W, Yi Z, et al., 2013. Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology (Berl) 230 (1): 49-55.
20. Centorrino F, Hernan MA, Drago-Ferrante G, et al., 2001. Factors associated with noncompliance with psychiatric outpatient visits. Psychiatr Serv 52 (3): 378-380.
21. Chiu HJ, Wang YC, Liou YJ, Lai IC, Chen JY,. 2003. Association analysis of the genetic variants of the N-methyl d-aspartate receptor subunit 2b (NR2b) and treatment-refractory schizophrenia in the Chinese. Neuropsychobiology 47 (4): 178-181.
22. Corbett R, Camacho F, Woods AT, et al., 1995. Antipsychotic agents antagonize non-competitive N-methyl-d-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 120 (1): 67-74.
23. Cosgrove VE, Suppes T,. 2013. Informing DSM-5: Biological boundaries between bipolar I disorder, schizoaffective disorder, and schizophrenia. BMC Med 11 (127): 1-7.
24. Creese I, Burt DR, Snyder SH,. 1976. Dopamine receptors and average clinical doses. Science 194 (4264): 546.
25. CRESTAR 2011. CRESTAR: Development of pharmacogenetic biomarkers for schizophrenia. Available: Http://www.crestar-project.eu/[2014, March/14].
26. Daly DA, Moghaddam B,. 1993. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 152 (1-2): 61-64.
27. Davis JM, Chen N, Glick ID,. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 (6): 553-564.
28. Di Maria E, Gulli R, Begni S, et al., 2004. Variations in the NMDA receptor subunit 2B gene (GRIN2B) and schizophrenia: A case-control study. Am J Med Genet B Neuropsychiatr Genet 128B (1): 27-29.
29. Dorval KM, Wigg KG, Crosbie J, et al., 2007. Association of the glutamate receptor subunit gene GRIN2B with attention-deficit/hyperactivity disorder. Genes Brain Behav 6 (5): 444-452.
30. Dudbridge F,. 2008. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 66 (2): 87-98.
31. Elkis H, Meltzer HY,. 2007. Refractory schizophrenia. Rev Bras Psiquiatr (Sao Paulo, Brazil: 1999) 29 (2): S41-7.
32. Emsley R, Rabinowitz J, Medori R, Early Psychosis Global Working Group. 2007. Remission in early psychosis: Rates, predictors, and clinical and functional outcome correlates. Schizophr Res 89 (1-3): 129-139.
33. Endele S, Rosenberger G, Geider K, et al., 2010. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet 42 (11): 1021-1026.
34. Evins AE, Amico ET, Shih V, Goff DC,. 1997. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm (Vienna Austria 1996 104 (6-7): 761-766.
35. Fitzgerald LW, Deutch AY, Gasic G, Heinemann SF, Nestler EJ,. 1995. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J Neurosci 15 (3 Pt 2): 2453-2461.
36. Freed WJ, Bing LA, Wyatt RJ,. 1984. Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice. Neuropharmacology 23 (2A): 175-181.
37. GAIN Collaborative Research Group, Manolio TA, Rodriguez LL, Brooks L, et al., 2007. New models of collaboration in genome-wide association studies: The Genetic Association Information Network. Nat Genet 39 (9): 1045-1051.
38. Galderisi S, Bucci P, Üçok A, Peuskens J,. 2012. No gender differences in social outcome in patients suffering from schizophrenia. Eur Psychiatry 2012 Aug 27 (6): 406-8.
39. Gauderman WJ,. 2002. Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 21 (1): 35-50.
40. Gauderman WJ, Morrison JM,. 2006. QUANTO: A computer program for power and sample size calculations for genetic-epidemiology studies. Version 1 (2): 4.
41. Ghassabian S, Chetty M, Tattam BN, et al., 2010. The participation of cytochrome P450 3A4 in clozapine biotransformation is detected in people with schizophrenia by high-throughput in vivo phenotyping. J Clin Psychopharmacol 30 (5): 629-631.
42. Giardino L, Bortolotti F, Orazzo C, et al., 1997. Effect of chronic clozapine administration on [3H]MK801-binding sites in the rat brain: A side-preference action in cortical areas. Brain Res 762 (1-2): 216-218.
43. Gomes I, Collins A, Lonjou C, et al., 1999. Hardy-Weinberg quality control. Ann Hum Genet 63 (Pt 6): 535-538.
44. Gunduz-Bruce H, McMeniman M, Robinson DG, et al., 2005. Duration of untreated psychosis and time to treatment response for delusions and hallucinations. Am J Psychiatry 162 (10): 1966-1969.
45. Kay SR, Fiszbein A, Opler LA,. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (2): 261-276.
46. Hagg S, Spigset O, Mjorndal T, Dahlqvist R,. 2000. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 49 (1): 59-63.
47. Hardy GH,. 1908. Mendelian proportions in a mixed population. Sci (New York, NY) 28 (706): 49-50.
48. Harrow M, Grossman LS, Herbener ES, Davies EW,. 2000. Ten-year outcome: Patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Br J Psychiatry 177: 421-426.
49. Heresco-Levy U,. 2003. Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27 (7): 1113-1123.
50. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D,. 1996. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry 169 (5): 610-617.
51. Hirai H, Kirsch J, Laube B, Betz H, Kuhse J,. 1996. The glycine binding site of the N-methyl-d-aspartate receptor subunit NR1: Identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region. Proc Natl Acad Sci USA 93 (12): 6031-6036.
52. Hong CJ, Yu YW, Lin CH, Cheng CY, Tsai SJ,. 2001. Association analysis for NMDA receptor subunit 2B (GRIN2B) genetic variants and psychopathology and clozapine response in schizophrenia. Psychiatr Genet 11 (4): 219-222.
53. Hopkins CR,. 2011. ACS Chem Neurosci molecule spotlight on RG1678. ACS Chem Neurosci 2 (12): 685-686.
54. Horacek J, Libiger C, Hoschl K, Borzova I, Hendrychova J,. 2001. "Clozapine-induced concordant agranulocytosis in monozygotic twins. Int J Psychiatry Clin Pract 5 (1): 71-73.
55. Hosking L, Lumsden S, Lewis K, et al., 2004. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet: EJHG 12 (5): 395-399.
56. Hoyer C, Kranaster L, Leweke FM, Klosterkotter J, Meyer-Lindenberg A, Koethe D,. 2010. Familial differential treatment response in schizophrenia-lessons from a case of three affected siblings. Pharmacopsychiatry 43 (5): 196-197.
57. Hwang R, Souza RP, Tiwari AK, et al., 2011. Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics 12 (2): 277-291.
58. Javitt DC, Zukin SR,. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (10): 1301-1308.
59. Jia P, Wang L, Fanous AH, et al., 2012. Network-assisted investigation of combined causal signals from genome-wide association studies in schizophrenia. PLoS Comput Biol 8 (7): E1002587.
60. Kane J, Honigfeld G, Singer J, Meltzer H,. 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 (9): 789-796.
61. Kargieman L, Santana N, Mengod G, Celada P, Artigas F,. 2007. Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine. Proc Natl Acad Sci USA 104 (37): 14843-14848.
62. Kay SR, Fiszbein A, Opler LA,. 1987. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (2): 261-276.
63. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC,. 2014. The social and economic burden of treatment-resistant schizophrenia: A systematic literature review. Int Clin Psychopharmacol 29 (2): 63-76.
64. Kharazia VN, Phend KD, Rustioni A, Weinberg RJ,. 1996. EM colocalization of AMPA and NMDA receptor subunits at synapses in rat cerebral cortex. Neurosci Lett 210 (1): 37-40.
65. Kohlrausch FB,. 2013. Pharmacogenetics in schizophrenia: A review of clozapine studies. Rev Bras Psiquiatr (Sao Paulo Brazil (1999) 35 (3): 305-317.
66. Komuro H, Rakic P,. 1993. Modulation of neuronal migration by NMDA receptors. Science 260 (5104): 95-97.
67. Kubota T, Jibiki I, Enokido F, Nakagawa H, Watanabe K,. 2000. Effects of MK-801 on clozapine-induced potentiation of excitatory synaptic responses in the perforant path-dentate gyrus pathway in chronically prepared rabbits. Eur J Pharmacol 395 (1): 37-42.
68. Kumra S, Frazier JA, Jacobsen LK, et al,. 1996. Chldhood-onset schizophrenia A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53: 1090-1097.
69. Kuryatov A, Laube B, Betz H, Kuhse J,. 1994. Mutational analysis of the glycine-binding site of the NMDA receptor: Structural similarity with bacterial amino acid-binding proteins. Neuron 12 (6): 1291-1300.
70. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV,. 2002. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature. J Clin Psychiatry 63 (10): 892-909.
71. Lahiri DK, Jr Nurnberger JI,. 1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19 (19): 5444.
72. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA,. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology 25 (4): 455-467.
73. Laube B, Hirai H, Sturgess M, Betz H, Kuhse J,. 1997. Molecular determinants of agonist discrimination by NMDA receptor subunits: Analysis of the glutamate binding site on the NR2B subunit. Neuron 18 (3): 493-503.
74. Lieberman JA, Safferman AZ, Pollack S,. 1994. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry 151 (12): 1744-1752.
75. Lindenmayer J, Apergi F,. 1996. The relationship between clozapine plasma levels and clinical response. Psychiatr Ann 26 (7): 406-412.
76. Linn GS, Negi SS, Gerum SV, Javitt DC,. 2003. Reversal of phencyclidine-induced prepulse inhibition deficits by clozapine in monkeys. Psychopharmacology (Berl) 169 (3-4): 234-239.
77. Liu N, Zhao H, Patki A, Limdi NA, Allison DB,. 2011. Controlling Population Structure in Human Genetic Association Studies with Samples of Unrelated Individuals. Stat Interface 4 (3): 317-326.
78. Long AD, Langley CH,. 1999. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res 9 (8): 720-731.
79. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R,. 1959. Study of a new schizophrenomimetic drug; sernyl. AMA Arch Neurol Psychiatry 81 (3): 363-369.
80. Luisada PV,. 1978. The phencyclidine psychosis: Phenomenology and treatment. NIDA Res Monogr 21 (21): 241-253.
81. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D, Breier A,. 1997. Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 42 (8): 664-668.
82. Mandich P, Schito AM, Bellone E, et al., 1994. Mapping of the human NMDAR2B receptor subunit gene (GRIN2B) to chromosome 12p12. Genomics 22 (1): 216-218.
83. Martucci L, Kennedy J,. 2010. Predicting negative symptom change during drug treatment, United States Patent,US 7,794,934 issued Sept 14 2010.
84. Massey PV, Johnson BE, Moult PR, et al., 2004. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci 24 (36): 7821-7828.
85. Mata I, Madoz V, Arranz MJ, Sham P, Murray RM,. 2001. Olanzapine: Concordant response in monozygotic twins with schizophrenia. Br J Psychiatry 178 (1): 86.
86. 2+ of NMDA responses in spinal cord neurones. Nature 309 (5965): 261-263.
87. McAdams LA, Harris MJ, Bailey A, et al., 1996. Validating specific psychopathology scales in older outpatients with schizophrenia. J Nerv Ment Dis 184: 246-251.
88. McGlashan TH,. 1988. A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 14 (4): 515-542.
89. Meltzer HY, Matsubara S, Lee JC,. 1989. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251 (1): 238-246.
90. Meltzer HY, Okayli G,. 1995. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry 152 (2): 183-190.
91. Meshul CK, Bunker GL, Mason JN, Allen C, Janowsky A,. 1996. Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J Neurochem 67 (5): 1965-1973.
92. Miyamoto S, Duncan GE, Marx CE, Lieberman JA,. 2005. Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10 (1): 79-104.
93. Mortensen PB, Norgaard-Pedersen B, Waltoft BL, et al., 2007. Toxoplasma gondii as a risk factor for early-onset schizophrenia: Analysis of filter paper blood samples obtained at birth. Biol Psychiatry 61 (5): 688-693.
94. Mortimer AM,. 2007. Symptom rating scales and outcome in schizophrenia. Brit J Psychiatry, Supplemental 50: S7-S14.
95. Newman-Tancredi A, Chaput C, Verriele L, Millan MJ,. 1996. Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors. Neuropharmacology 35 (1): 119-121.
96. Ninan I, Jardemark KE, Wang RY,. 2003. Differential effects of atypical and typical antipsychotic drugs on N-methyl-d-aspartate- A nd electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex. Synapse 48 (2): 66-79.
97. Noda Y, Yamada K, Furukawa H, Nabeshima T,. 1995. Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: A new model of schizophrenia. Brit J Pharmacol 116 (5): 2531-2537.
98. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A,. 1984. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307 (5950): 462-465.
99. Nyholt DR,. 2004. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74 (4): 765-769.
100. Odom-White A, de Leon J,. 1996. Clozapine levels and caffeine. J Clin Psychiatry 57 (4): 175-176.
101. Ossowska K, Pietraszek M, Wardas J, Nowak G, Wolfarth S,. 1999. Chronic haloperidol and clozapine administration increases the number of cortical NMDA receptors in rats. Naunyn Schmiedebergs Arch Pharmacol 359 (4): 280-287.
102. Overall EJ, Gorham DR,. 1962, The Brief Psychiatric Rating Scale. Psychol Rep 10: 799-812.
103. Overall JE, Rhoades HM,. 1982. Refinement of phenomenological classification in clinical psychopharmacology research. Psychopharmacology (Berl) 77: 24-30.
104. Palego L, Biondi L, Giannaccini G, et al., 2002. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: Influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 26 (3): 473-480.
105. Park S, Jung SW, Kim BN, et al,. 2013. Association between the GRM7 rs3792452 polymorphism and attention deficit hyperactivity disorder in a Korean sample. Behav Brain Funct 9: 1-9081-9-1.
106. Paschou P, Drineas P, Lewis J,. 2008. Tracing sub-structure in the European American population with PCA-informative markers. PLoS Genet 4 (7): E1000114.
107. Patil ST, Zhang L, Martenyi F, et al., 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med 13 (9): 1102-1107.
108. Pearce IA, Cambray-Deakin MA, Burgoyne RD,. 1987. Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells. FEBS Lett 223 (1): 143-147.
109. Perkins DO, Gu H, Boteva K, Lieberman JA,. 2005. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. Am J Psychiatry 162 (10): 1785-1804.
110. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez, R, Rapaport, MH,. 1992, "Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Arch Gen Psychiatry 49 (5): 345-353.
111. Pilowsky, LS, Bressan, RA, Stone, JM,. 2006. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients ", Mol Psychiatry 11 (2): 118-119.
112. Pinard E, Alanine A, Alberati D, et al., 2010. Selective GlyT1 inhibitors: Discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem 53 (12): 4603-4614.
113. Price AL, Butler J, Patterson N, et al., 2008. Discerning the ancestry of European Americans in genetic association studies. PLoS Genet 4 (1): E236.
114. Purcell S, Neale B, Todd-Brown K, et al., 2007. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81 (3): 559-575.
115. Purkayastha S, Ford J, Kanjilal B, et al., 2012. Clozapine functions through the prefrontal cortex serotonin 1A receptor to heighten neuronal activity via calmodulin kinase II-NMDA receptor interactions. J Neurochem 120 (3): 396-407.
116. Sadee W,. 2012. The relevance of "missing heritability" in pharmacogenomics. Clin Pharmacol Ther 92 (4): 428-430.
117. Sadee W,. 2013. Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example. J Pharm Sci 102 (9): 2924-2929.
118. Sasieni PD,. 1997. From genotypes to genes: Doubling the sample size. Biometrics 53 (4): 1253-1261.
119. Schiller J, Schiller Y, Clapham DE,. 1998. NMDA receptors amplify calcium influx into dendritic spines during associative pre- A nd postsynaptic activation. Nat Neurosci 1 (2): 114-118.
120. Schizophrenia Working Group of the Psychiatric Genomics Consortium. 2014. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511 (7510): 421-427.
121. Schmitt A, Zink M, Muller B, et al., 2003. Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem Res 28 (2): 235-241.
122. Schotte A, Janssen PF, Gommeren W, et al., 1996. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl) 124 (1-2): 57-73.
123. Seeman P, Lee T,. 1975. Antipsychotic drugs: Direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188 (4194): 1217-1219.
124. Seppala NH, Leinonen EV, Lehtonen ML, Kivisto KT,. 1999. Clozapine serum concentrations are lower in smoking than in non-smoking schizophrenic patients. Pharmacol Toxicol 85 (5): 244-246.
125. Shapiro M,. 2001. Plasticity, hippocampal place cells, and cognitive maps. Arch Neurol 58 (6): 874-881.
126. Solanki RK, Singh P, Munshi D,. 2009. Current perspectives in the treatment of resistant schizophrenia. Indian J Psychiatry 51 (4): 254-260.
127. St Clair D, Xu M,. 2005. Rates of adult schizophrenia following prenatal exposure to the Chinese famine of 1959-1961. Jama 294 (5): 557-562.
128. Sun T, Hu G, Li M,. 2009. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: Relevance to animal models of antipsychotic drugs. Eur J Pharmacol 602 (2-3): 334-342.
129. Susser ES, Lin SP,. 1992. Schizophrenia after prenatal exposure to the Dutch hunger winter of 1944-1945. Arch Gen Psychiatry 49 (12): 983-988.
130. Szczepankiewicz A, Skibinska M, Suwalska A, Hauser J, Rybakowski JK,. 2009. No association of three GRIN2B polymorphisms with lithium response in bipolar patients. Pharmac Rep: PR 61 (3): 448-452.
131. Tandon R, Fleischhacker WW,. 2005. Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment. Schizophr Res 79 (2-3): 145-155.
132. Theisen FM, Gebhardt S, Haberhausen M, et al., 2005. Clozapine-induced weight gain: A study in monozygotic twins and same-sex sib pairs. Psychiatr Genet 15 (4): 285-289.
133. Tian L, Stefanidakis M, Ning L, et al., 2007. Activation of NMDA receptors promotes dendritic spine development through MMP-mediated ICAM-5 cleavage. J Cell Biol 178 (4): 687-700.
134. Tingley WG, Ehlers MD, Kameyama K, et al., 1997. Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-d-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem 272 (8): 5157-5166.
135. 2 measure of linkage disequilibrium. Theor Popul Biol 74 (1): 130-7.
136. Ventura J, Nuechterlein KH, Lukoff D, Hardesty JP,. 1989. A prospective study of stressful life events and schizophrenic relapse. J Abnorm Psychol 98 (4): 407-11.
137. Vojvoda D, Grimmell K, Sernyak M, Mazure CM,. 1996. Monozygotic twins concordant for response to clozapine. Lancet 347 (8993): 61.
138. Weinberg W,. 1908. Über den Nachweis der Vererbung beim Menschen. Württemb 64: 369-382.
139. Wittke-Thompson JK, Pluzhnikov A, Cox NJ,. 2005. Rational inferences about departures from Hardy-Weinberg equilibrium. Am J Hum Genet 76 (6): 967-986.
140. World Medical Association. 2013, WMA declaration of Helsinki: Ethical principles for medical research involving human subjects. Available: Http://www.wma.net/en/30publications/10policies/b3/index.html [2014, 11/6].
141. Wyatt RJ, Henter I,. 2001, "Rationale for the study of early intervention. Schizophr Res 51 (1): 69-76.
142. Xia Z, Dudek H, Miranti CK, Greenberg ME,. 1996. Calcium influx via the NMDA receptor induces immediate early gene transcription by a MAP kinase/ERK-dependent mechanism. J Neurosci 16 (17): 5425-5436.
143. Xu Z, Taylor, JA,. 2009. SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 37 Web Server issue: W600-5.
144. Yamamoto BK, Cooperman MA,. 1994. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14 (7): 4159-4166.
145. Yoo HJ, Cho IH, Park M, Yang SY, Kim SA,. 2012. Family based association of GRIN2A and GRIN2B with Korean autism spectrum disorders. Neurosci Lett 512 (2): 89-93.
146. Zhang C, Li Z, Wu Z, et al., 2014. A study of N-methyl-d-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology (Berl) 231 (4): 685-693.
147. Zhao C, Sun T, Li M,. 2012. Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion. Prog Neuropsychopharmacol Biol Psychiatry 38 (2): 175-182.
148. Zuk O, Hechter E, Sunyaev SR, Lander ES,. 2012. The mystery of missing heritability: Genetic interactions create phantom heritability. Proc Natl Acad Sci USA 109 (4): 1193-1198.